1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trial
Gonzalez-Miro, Majela LU ; Pawlowski, Andrzej LU ; Lehtonen, Janne LU ; Cao, Duojia LU ; Larsson, Sara LU
; Darsley, Michael
; Kitson, Geoff
; Fischer, Per B.
and Johansson-Lindbom, Bengt
LU
(2023)
In iScience
26(3).
- Contribution to journal › Article
- 2022
-
Mark
A group B Streptococcus alpha-like protein subunit vaccine induces functionally active antibodies in humans targeting homotypic and heterotypic strains
Pawlowski, Andrzej LU ; Lannergård, Jonas LU ; Gonzalez-Miro, Majela LU ; Cao, Duojia LU ; Larsson, Sara LU
; Persson, Jenny J.
LU
; Kitson, Geoff
; Darsley, Michael
; Rom, Ane Lilleøre
and Hedegaard, Morten
, et al.
(2022)
In Cell Reports Medicine
3(2).
- Contribution to journal › Article
- 2021
-
Mark
The Maternal Group B Streptococcus Alpha-Like Protein Subunit Vaccine GBS-NN Targets Homotypic and Heterotypic Strains, Confers Opsonophagocytic Killing and Prevents in vitro Invasion of Human Epithelial Cells
Pawlowski, Andrzej LU ; Lannergård, Jonas LU ; Gonzalez-miro, Majela LU ; Cao, Duojia LU ; Larsson, Sara LU
; Persson, Jenny J.
LU
; Kitsson, Geoff
; Darsley, Michael
; Rom, Ane Lilleøre
and Hedegaard, Morten
, et al.
(2021)
p.1-58
- Working paper/Preprint › Preprint in preprint archive
-
Mark
Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women
- Contribution to journal › Article